Novo Nordisk
Novo Nordisk Articles
Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline, 24/7 Wall St. projects huge upside through the end of the decade.
Published:
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to...
Published:
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over. It said the Danish pharmaceutical had sufficient supply of its...
Published:
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to...
Published:
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists...
Published:
